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Ronald L. Grier, DVM, PhD* *
EditorJs note: Currently, photoradiation
therapy is not performed in the Veterinary
Teaching Hospital at Iowa State University.
Introduction
One of the most difficult areas of both hu-
man and veterinary medicine today is the
treatment of neoplastic disease. Numerous
techniques and agents have been used in this
field but none are totally effective. The varia-
bility of responses to treatment is as wide as the
variety of cancerous conditions. For this rea-
son, research continues to search for safer,
more effective methods of cancer therapy. One
development in this area is phototherapy, or
more exactly, photoradiation therapy (PRT).
This technique was expanded to include its use
in pets. 21
Photoradiation therapy involves use of a
photoactive drug which localizes in neoplastic
and dysplastic tissues while at the same time
rapidly clearing from normal tissues. Illumina-
tion with red light electronically excites the
compound in the malignant tissue; energy is
released, cell components oxidize and cell
death occurs. Normal tissue is thus spared
while malignant tissue is destroyed. 1
History
The theory that drugs cause a photosensitiv-
ity reaction in tissues is not new.2Thirty years
ago it was noted that hematoporphyrins accu-
mulated in embryonic, neoplastic, and re-
generating tissues, and in lymph nodes. Tu-
mors fluoresced a red color when illuminated
with ultraviolet light after injection of a crude
hematoporphyrin compound. In 1960 a puri-
fied compound, hematoporphyrin derivative
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(Hpd), was found to have. a superior tumor-
localizing ability.3 In 1973 the Mayo Clinic re-
ported the use of fluorescence bronchoscopy in
early lung cancer. However, the fluorescence
\vas faint and hard to document and so the
project was discontinued. 2 The first reported
case of complete tumor destruction of experi-
mental tumors was in 1975 when Hpd was
used with local application of red light the fol-
lowing day. In 1976 this treatment was used on
a human bladder carcinoma with light applica-
tion via a transurethral quartz rod. '1
Biochemistry
While Hpd is selectively retained by malig-
nant tissue it is ~lso retained by liver, kidney,
spleen, and lymphS Studies indicate that the
relative hydrophobicity of a porphyrin is very
important to both its localization and tissue
toxicity. More hydrophilic agents do not accu-
mulate well and therefore are very poor photo-
sensitizers of intact cells. The porphyrin struc-
ture also affects the toxic products formed and
the speed of their formation. Studies showed
that hematoporphyrin has difficulty crossing
cell membranes; localization in malignant tis=
sues occurs as a result of intercellular conver-
sion of a permeable derivative to hemato-
porphyrin or another poorly diffusible
component. 6
How are such toxic compounds formed and
how do they destroy the tissues? The reaction
is a photo-initiated oxidation in which energy
is transferred from the Hpd to tissue oxygen,
forming singlet oxygen:
Hpd + hv - 1Hpd*
1Hpd*- 3Hpd*
3Hpd* + 302 - 102 + Hpd
102 + substrate - oxidation
102 - 302
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In this reaction 1H pd* is the excited state of
Hpd, 3Hpd* is the excited triplet state of Hpd,
302 is ground state triplet oxygen and 102 is the
excited triplet state of oxygen. 7,8
The occurrence of such a reaction has been
inferred from the protective effect provided by
the presence of natural or added carotenoids
which are well-established quenchers of singlet
oxygen. Using 1,3-diphenylisobenzofuran as a
quencher of photoactivation, studies have con-
firmed that singlet oxygen is the likely cytotox-
ic agent with this type of therapy.8 Immediately
after exposure to PRT, coagulation of erythro-
cytes occurs in tumor vessels where the por-
phyrin levels are highest. Death of nearby cells
occurs and more distant cells become less
tightly packed. Electron microscopy shows that
cells nearest the vessels are actually emptied of
cytoplasmic contents which have leaked into
the interstitium. Within three hours gross ne-
crosis and massive cell destruction are seen.
This is a manifestation of inhibition of mem-
brane transport, membrane damage due to
photodynamic crosslinking of membrane pro-
teins and lipids, and damage to DNA and lyso-
somes. Survival curves for cells containing
H pd are similar to those resulting from ioniz-
ing radiation. 7
Having established that such a reaction oc-
curs, it was desirable to find a light source pro-
ducing wavelengths of 620-640 nanometers.
This range was found to produce optimal re-
sults since visible wavelengths greater than 600
nm are least absorbed by skin and other tis-
sues, and porphryrins show weak absorption in
this part of the spectrum. Arc lamps, fluores-
cent lights and other strong light sources will
deliver enough light to treat superficial tumors
when fitted with appropriate filters. 9 Deeper
tumors require a different method of light de-
livery. New developments in lasers and fi-
beroptics can be used to allow illumination of
nearly any portion of the body without major
surgery. In man, tumors up to 5cm X 5cm
have been destroyed by use of multiple fiber
techniques. 10
Human Medicine Applications
Many preclinical tests and trials of PRT
have been done in man. In all cases the lesions
treated have been inoperable and have failed to
respond to conventional therapy. The amount
of Hpd used, the wavelength and duration of
light exposure and many other parameters
have been studied. Favorable response oc-
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curred with many types of neoplasia and in
numerous anatomical locations. PRT has also
been shown to be effective in localization of
some malignancies.
PRT has been used to treat squamous cell
carcinoma of the tracheobronchial tree in 10
patients. 11 Laser beams were used to deliver
light through a bronchoscope. Complete re-
sponse (no tumor demonstrable in a biopsy or
brush preparation) was seen in four cases, and
a partial response (greater than 50 % decrease
in tumor size) occurred in five patients. All
masses had been small superficial tumors. The
remaining patient died from hemorrhage and
cardiac arrest secondary to the neoplasm erod-
ing the wall of a major bronchus. ll
In Australia, researchers used Hpd and a
laser/fiberoptic system to treat 20 superficial
and seven deeper tumors which included mam-
mary carcinoma and other carcinomas, malig-
nant melanoma, chondrosarcoma and glioma.
The best clinical results were seen with superfi-
cial tumors, with a positive response in 17 of 20
cases. Complete tumor necrosis occurred in
five. There was no response in two malignant
melanomas and a metastatic chondrosarcoma.
Of the seven tumors, only the glioma showed
any response (See Table 1).
Two studies with PRT have been done at the
University of California on dermal breast can-
cer recurrence, local recurrence of head and
neck squamous cell carcinoma, and other car-
cinomas. One study reported a 67 % favorable
response involving treatment of 128 sites. The
best response was against local recurrence of
head and neck squamous cell carcinoma and
recurrence of breast cancer with an 85 % and
70% response rate respectively. A lesser re-
sponse was seen with metastatic squamous cell
carcinoma in which the tumors were usually
larger, ulcerated and more severe at the time of
treatment. Response was evaluated 30 days
post-treatment; a positive response was defined
as either complete or partial. 12 In another study
from the University of California, PRTwas
used on 267 tumor sites which included dermal
breast carcinoma recurrence, head and neck
squamous cell carcinoma recurrence and cuta-
neous metastasis. An 81 % postitive response
rate was seen (complete and partial response).
Some patients with recurrent breast cancer ex-
perienced significant pain for up to three weeks
following treatment. Interestingly, while 84 tu-
mors responded favorably, only 25 % of 'these
had an effect on the course of the disease.
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TABLE 1 Current statistics for tumor responses to phototherapy (6/1/83)
Response
Tumor No. Complete* Partial None No Follow-up
Adenocarcinoma (Mammary - Cat) 5 5
Adenocarcinoma (Undifferentiated) 3 1 2
Adamantinoma 4 4(3)"
Eosinophilic Granuloma 1
Fibromatous Epulus 2 1(1)"
Acanthomatous Epulus 1 1
Fibroma 1 1





Malignant Mast Cell 12 9(2)" 2
Malignant Melanoma (Melanotic) 4 3(2)" 1
Malignant Melanoma (Amelanotic) 3 2(1)" 1
Mastocytoma 1 1
Myxoma 2 1 1
Osteosarcoma (Head) 6 3(3)- 2 1
Osteusarcoma (Limb) 3 1~ 2
Perianal Gland Sarcoma 1 1
Sarcoma (Undifferentiated) 2 2
Sebacious Gland Sarcoma 1 1(1)-
Sebacious Gland Carcinoma 1 1
Squamous Cell Carcinoma 8 3(1)- 4
Synovial Cell Sarcoma 3 1 2
Total types: 25 75 44 23 5 3
or or or or
59% 31 % 7% 4%
90% Total positive response
(*Number in parentheses are those in complete remission for more than one year.)
[Thoma, Stein, Weishaupt, and Dougherty: Phototherapy: a promising cancer therapy. VMISAC 78:1965, 1983.]
Many patients developed new lesions in un-
treated areas. Patients with cutaneous metas-
tatic head and neck tumors did not do well, but
those with local recurrence benefitted consider-
ably with a major change in disease progres-
sion. 12 ,13
Several other anatomical locations and tu-
mors have been treated with PRT. The Japa-
nese have reported complete regression of early
vaginal carcinomas with PRT treatment, with
no recurrence at one-year follow-up.14 Hpd
and a laser light source have been used to treat
retinoblastomas and intraocular malignant me-
lanoma of the choroid. Treatment in this area
is normally difficult, as adjacent normal tissue
must be spared. Radiation therapy results in
radiation burn of nearby tissue. This problem
does not occur with PRT if the light intensity
remains less than 200 milliwatts/cm2 • 15 PRT is
also being considered for malignant brain tu-
mors. Some work has been done in this area,
but conclusions cannot be drawn at this time. 16
An interesting facet of current PRT research
is the use of Hpd and fluorescence bronchosco-
py for the detection and localization of bron-
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chial and lung cancer. In the past when sputum
cytology suggested neoplasia, a brush biopsy or
tissue biopsy had to be prepared. These proce-
dures were often difficult to perform if the le-
sion could not be visibly differentiated from the
surrounding tissue. With PRT, Hpd was given
intravenously and the areas were checked three
hours later for fluorescence. The results were
quite favorable with fluorescence seen in 32 of
34 malignancies. No false positives were seen
in the eight benign lesions. A few false positives
were seen in areas of lymphoid tissue, but this
was not a problem since all true positives were
later confirmed by biopsy. False negatives are
more of a problem since the lesion could then
be missed. 17,18,19 This same technique for locali-
zation of neoplasia has been used on bladder
carcinoma. Biopsies of visually suspicious areas
have previously been the primary method of
confirming positive urine cytology. Subtle or
diffuse disease was often missed by this
method, however. Hpd given intravenously
two hours pre-surgery will localize in dysplastic
and neoplastic transitional cells and be detected
by subsequent fluorescence. 20
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Side effects have been relatively mild. Slight
pain has been experienced in a few cases and
some discomfort has been associated with re-
sultant tumor necrosis. The main complication
is photosensitivity for 2-4 weeks post-treat-
ment. This can be prevented however, if the
patient avoids exposure to sun during this
time. A few patients who have ignored this ad-
vice have incurred skin burns.
Veterinary Medicine Applications
PRT has been used in pet dogs and cats in
the past few years. The animals used in this
ongoing study were chosen because of their
failure to respond to conventional therapy or
because they could not tolerate therapy. Some
pets had surgical excision of tumor with PRT
used as adjunct therapy. The pets were ob-
tained directly from their owners after having
discussed all treatment alternatives and the in-
vestigational status of Hpd/PRT. The animals
were returned to their owners following treat-
ment. Radiology was used to determine the
size and extent of the mass, presence of metas-
tasis and to aid in fiberoptic placement in tu-
mors to be treated. All lesions were confirmed
by biopsy and histopathology. 10,21 Other tests
such as electrocardiograms, urinalyses, and
microbial cultures were performed if deemed
necessary. 10,21
The Hpd used was Photofrin-Va , which is
produced by dissolving hematoporphryin in
glacial acetic acid and sulphuric acid. The solu-
tion was filtered and neutralization with so-
dium acetate formed a precipitate. The precip-
itate was washed and stored at - 20°C until
needed. For injection, one part Hpd was mix-
ed with sodium hydroxide, neutralized with
hydrochloric acid, and diluted with sodium
chloride to a final concentration of 5mg/ml.
Millipore filtration rendered the solution
sterile. 1
Two to three days prior to light treatment,
3.0 to 5.0 mg/kg Hpd was injected intrave-
nously. This allowed adequate drug concentra-
tion in the tumor and clearance by normal tis-
sues. During this time the animals were kept
out of sunlight or bright light to minimize pho-
tosensitivity reactions. Photosensitivity appears
as a transient sunburn/edema/erythema reac-
tion that is reversible with antihistamines.
Minimal problems have been observed in ani-
mals ~ue to their pigmentation and hair coat.
aOncology Research and Development, Inc., Cheekto-
waga, NY.
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At the time of light treatment the ~nimals
were anesthetized with thiamylal sodium and
halothane, or xylazine and ketamine. The area
of the tumor was clipped and prepped for sur-
gery. The treatment light source was produced
by an argon ion laser. This produced enough
light energy to pump a Rhodamine B dye laser
operating without the tuning element. A broad
output spectrum between 625 and 640 nm re-
sulted which was then narrowed to 630 ± 2
nm with a birefringent filter. The beam was
split into four beams and coupled with fiberop-
tics. Coupling efficiency was greater than 70%
within the fiber lengths used. The ends of the
fibers were cut optically flat after stripping
back 1-2 cm of the protective teflon coating.
If the mass was less than 1.0-1. Scm in
diameter, four 18-gauge needles were inserted
in the tumor in a tetrahedral pattern with lcm
sides. The optical fibers, having been cold
sterilized and cleaned with 70% ethanol, were
inserted through the needles to a distance Imm
beyond the needle tips. If excessive bleeding
occurred through the needle, the needle and
fiber were withdrawn and reinserted a short
distance away. This was necessary since hemo-
globin absorbs light slightly at 630nm.
If the tumor was greater than 2cm in diame-
ter, the fibers were implanted in several areas
sequentially to ensure light delivery throughout
the mass and the most adjacent normal tissue.
Treatment times ranged from 15-30 minutes
at 120-900 milliwatts/fiber but was deter-
mined to be optimal at 20 minutes at 250mW/
fiber. This delivered 300 Joules/fibyr/insertion.
Total time for a treatment session was usually 2
hours. With large tumors surgical debulking
was performed one week prior to phototherapy
to lessen treatment time and decrease the
amount of necrotic tissue. During treatment,
power was increased slowly and the light
emanating from the tumor was observed to en-
sure proper light levels and adequate fiber posi-
tioning.
As PRT proceeded, the tumor increased in
size due to edema and cell necrosis; some tu-
mors also appeared dark or discolored due to
necrosis. The edema usually regressed in 48
hours. Tissue response ranged from fluid
drainage to severe frank necrosis and
sloughing. Granulation and healing occurred
at a normal rate, and by three weeks, deter-
mination of tumor regrowth was possible.
There are no contraindications to repeated
treatments as long as it is safe for the animal to
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again be anesthetized. Large tumors that could
not be surgically reduced prior to PRT were
retreated at close intervals; with such a treat-
ment schedule the dose of Hpd should be de-
creased by one-third or one-half if given within
four to six days of the previous injection.
Post-treatment care was similar to that for
any surgical procedure. Doxorubicin HCl
(Adriamycin®) is the only known drug to be
contraindicated. Antibiotics, steroids, fluids,
cleansing of the sloughing tissue, diuretics, and
other compounds all were used as needed. The
patients were rechecked weekly for at least one
month and then monthly if all seemed to be
progressing well. Chemotherapy other than
doxorubicin may be used in an effort to control
micrometastasis. 5,6,21
The results of PRT on pets have been very
encouraging for certain types of solid malig-
nant tumors. Table 1 gives the results of PRT
in 75 animals with 25 histological tumor types.
Seventeen have been in remission for over a
year and 44 (59%) are in complete remission.
Partial response was seen in an additional 23
cases. Those tumors unresponsive to the thera-
py were in the long bones of the extremities
(two osteosarcomas, one myxoma, and one fi-
brosarcoma). Three animals were lost to fol-
low-up. The longest follow-up is of a cat
treated for osteogenic sarcoma of the mandible
SIX years ago.
Favorable response was seen with osteosar-
con1a of the head, malignant melanoma, fibro-
sarcoma, malignant mast cell sarcoma, ada-
mantinoma and synovial cell carcinoma. Both
favorable and unfavorable responses were seen
with squamous cell carcinoma, adenocarcino-
ma, leiomyosarcoma, and hemangiopericyto-
rna. The differences in response have not been
explained but are similar to those being seen in
human medicine. Many variables can affect
the response of the tumor to therapy. Altera-
tion of the circulation to the tumor may change
the amount of Hpd being delivered to the
mass. Passage of the drug into the tumor cells
and surrounding tissue are dependent on the
permeability of the tumor vessels. Tissue den-
sity (e.g. bone or melanin granules) can alter
the penetrating ability of light. Less under-
stood variables, such as the fact that osteogenic
sarcoma of the head is more osteoblastic while
osteogenic sarcoma of the limbs is more lytic,
also may playa part. 5,6
Summary
Phototherapy looks to be a very promising
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new development in the field of oncology and
the treatment of discrete solid tissue tumors. It
is showing itself to be very effective and reliable
for several histopathologic types of tumors
which do not respond well to presently avail-
able modalities. One such tumor is the os-
teogenic sarcoma of the head. Not only has
photoradiation therapy eradicated some tu-
mors, but it does so without damage to adja-
cent healthy tissue. This allows the healthy tis-
sues to fill-in the defect and remodel the bone.
Good results (complete remission) were also
seen with mammary adenocarcinomas in the
cat. This highly malignant neoplasia pre-
viously carried a poor prognosis even with sur-
gery.
The ability to deliver light directly to the
tumor via fiberoptics extends the use of PRT
to any site reached by needles or an endoscope.
Previously, chemotherapy or surgery were the
main alternatives for neoplasia of the lungs,
throat, bladder, vagina, and colon. PRT may
be a safer, less-invasive alternative.
The technique is a simple one, making it a
good procedure for the practitioner. The cost of
the equipment is prohibitive at the current
time, but it has been proposed that a metropol-
itan area with a population of greater than
750,000 could produce enough cases to justify
a regional unit. 5 Furthern10re, as lower cost
light sources are developed, PRT could be put
into even more widespread use.
Problems remain to be further investigated.
More work is needed to determine exactly why
some types of neoplasia do not respond to
treatment. The recurrence of new squamous
cell lesions adjacent to the site of previous
treatment points to the need to develop better
ways to initially evaluate the extent of the le-
sions. It would be helpful to be able to assay for
Hpd levels to predict response to treatment and
plan further therapy; currently no such assay is
available. 21 Lastly, large tumors require long
and/or repeated periods of anesthesia which
may not be well tolerated by some patients; a
larger dose of Hpd to increase the effective
treatment volume and the coupling of multiple
fibers to the laser are being investigated. 21
As with any tumor treatment protocol, PRT
has its advantages and disadvantages. Its
adaptability, however, allows it to be effectively
used as a primary treatment or as an adjuvant
to surgery or as an alternative to radiation and
chemotherapy. With time and further study
and development, its benefits are increasing
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and its limitations are decreasing. The clinical
simplicity and apparent safety of this therapy
makes it possible that PRT n~ay soon take a
place alongside the more conventional tumor
therapies.
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